TaiMed Biologics Inc. (TPEX:4147)
Taiwan
· Delayed Price · Currency is TWD 79.60
-1.00 (-1.24%)
Apr 24, 2025, 1:30 PM CST
TaiMed Biologics Revenue
In the year 2024, TaiMed Biologics had annual revenue of 610.16M TWD with 24.07% growth. TaiMed Biologics had revenue of 145.77M in the quarter ending December 31, 2024, a decrease of -7.87%.
Revenue
610.16M
Revenue Growth
+24.07%
P/S Ratio
36.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
22.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 610.16M | 118.39M | 24.07% |
| Dec 31, 2023 | 491.78M | -71.23M | -12.65% |
| Dec 31, 2022 | 563.01M | 149.57M | 36.18% |
| Dec 31, 2021 | 413.44M | -309.04M | -42.78% |
| Dec 31, 2020 | 722.49M | 17.98M | 2.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |